Arsenal Biosciences
Arsenal Biosciences raises $325M Series C
Quick Facts
Arsenal Biosciences: Series C Funding Round
Arsenal Biosciences has successfully raised $325M in Series C funding.
Company Overview
Cell therapy company developing programmable T-cell therapies for solid tumors
Funding Details
The Series C round was led by Arch Venture Partners, with participation from T. Rowe Price Associates.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2019
- Employees: 150+
- Category: HealthTech
Investment
Arsenal Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Arch Venture Partners: Verified investor in Series C
- T. Rowe Price Associates: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
